Αρχική Uncategorized New Imaging Tool Could Predict Whether Hormone Therapy Will Work in Breast...

New Imaging Tool Could Predict Whether Hormone Therapy Will Work in Breast Cancer Patients

Hormone therapy is a go-to treatment for estrogen receptor-positive breast cancer and is often very effective. However, about half of patients who get this treatment don’t see the same benefits as others. A new approach may be able to determine who will respond well and who won’t.

Researchers from Washington University School of Medicine in St. Louis developed an imaging test that measures how well estrogen receptors are functioning in a patient’s cancer cells. They found that high functioning estrogen receptors led to stable or improved outcomes with hormone therapy, while nonfunctional estrogen receptors saw cancer continue to progress, despite the hormone therapy. The results were published in the February 2 edition of Nature Communications.

PHOTO: PIXABAY/BOKSKAPET

Senior author Dr. Farrokh Dehdashti, along with Dr. Barry A. Siegel and Dr. Marilyn J. Siegel, says, “If breast cancer in a patient is estrogen receptor-positive, doctors will usually recommend hormone therapy even though they know it will only work for slightly more than half the patients. When hormone therapy works, it’s typically quite effective, and it has milder side effects than some other therapies, and that’s why oncologists and patients want to try it first. But we need to narrow down who is likely to benefit, and there really hasn’t been a reliable test to accomplish that.”

Around 80% of breast cancer cases are estrogen-receptor positive. That means the cancer cells carry estrogen receptors and the tumor grows due to naturally occurring estrogen in the body. Doctors use hormone therapy to attempt to block the effects estrogen has on the tumor. This can be done through a variety of drugs, including those that prevent the body from making estrogen and those that specifically block the estrogen receptor on cancer cells. Pre-menopausal women usually have a different type of hormone therapy because their bodies are still producing large amounts of estrogen.

The researchers say doctors have long believed that the women who don’t respond well to hormone therapy don’t have functioning estrogen receptors within their cancer cells, and the team at Washington University School of Medicine took this theory into mind with an imaging test.

PHOTO: ADOBE STOCK/HERO IMAGES

When estrogen receptors are stimulated, cells respond by producing more progesterone receptor molecules on their surfaces. Researchers developed an imaging agent that measured the number of progesterone receptors on those cells. The compound attaches to the receptors and can be detected as part of a positron emission tomography (PET) scan. The PET signal increases with higher levels of progesterone receptors.

The study applied this method to 43 postmenopausal women with estrogen receptor-positive breast cancer, 86% of whom had metastatic disease. Nearly three-quarters had already received some kind of treatment, usually a type of hormone therapy. The women had an initial PET scan, followed by another after they’d been administered three doses of estrogen over a 24-hour period.

The PET signal in the tumor increased substantially after estrogen exposure in 28 women, meaning their estrogen receptors were working. The other 15 saw little impact. After this, researchers followed the participants for six months throughout their hormone therapy. Of the 15 who had little reaction to the estrogen, all saw their tumors progress. The ones who saw a reaction to the estrogen, meanwhile, all either improved or held stable.

PHOTO: ADOBE STOCK/WAVEBREAKMEDIAMICRO

Dehdashti says, “The goal of therapy is to control or improve disease, so if the therapy is likely to be ineffective, it should not be given to a patient. We observed 100% agreement between the response to estrogen challenge and the response to hormone therapy, even though the participants were on a variety of treatment regimens. This method should work for any therapy that depends on a functional estrogen receptor, and it could provide valuable information to oncologists deciding how best to treat their patients.”

Article continues below

Our Featured Programs

See how we’re making a difference for People, Pets, and the Planet and how you can get involved!

To confirm their results, the researchers are now working on getting a larger phase 2 clinical trial underway.

The American Cancer Society says hormone therapy can be used before or after surgery to lower the risk of a recurrence of cancer. It will typically be used for at least five to ten years. It also serves as a treatment for those who have seen their cancer return or spread.

Provide Mammograms

Support those fighting Breast Cancer at The Breast Cancer Site for free!

Whizzco Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Despite Proven Safety of HPV Vaccines, More Parents Have Concerns

October 22, 2021, by NCI Staff Credit: National Cancer Institute Despite more than 15 years of consistent evidence that HPV vaccines are safe and effective, a...

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy...

Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities

Suzette Simon lost her mother to breast cancer. In 2020, she learned that she had the disease, as well. Realizing how much harder breast...

Why Wearing Comfortable Clothes During Cancer Treatment Matters

Voices on Cancer is an award-winning Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. Cindy Trice is...

Breast cancer surgery: ‘I’m proud of the tattoos inked across my chest’

Wendy had a double mastectomy in 2017 and remained flat. “When the consultant told me, I remember crying and saying that I have 2 young...

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of...